Literature DB >> 19755676

TC-PTP is required for the maintenance of MYC-driven B-cell lymphomas.

Ryan M Young1, Avital Polsky, Yosef Refaeli.   

Abstract

We sought to determine the contributions of protein tyrosine phosphatases (PTPs) to the pathogenesis of B-cell lymphomas. We found that T-cell PTP (TC-PTP) was overexpressed in transformed B cells. We hypothesized that TC-PTP may be a tumor-promoting gene that is regulated by MYC overexpression in B cells. Knockdown of TC-PTP in murine tumors resulted in decreased cell viability in vitro because of an arrest in the G(1) phase of the cell cycle. Furthermore, cells with reduced TC-PTP expression were unable to either engraft or expand in vivo. Taken together, these data indicate that TC-PTP is required for B-cell tumor maintenance. Our data also suggested a correlation between TC-PTP expression and MYC overexpression. To investigate this further, we used malignant murine B cells that contain a doxycycline-repressible MYC transgene. We found that repression of MYC overexpression with doxycycline reduced TC-PTP expression. Moreover, enforced expression of TC-PTP showed partial rescue of the expansion of tumor cells after suppression of MYC overexpression. These results suggest that MYC overexpression induces TC-PTP overexpression, which in turn promotes tumor proliferation, implicating TC-PTP as an important effector of the MYC-driven proliferation program in B-cell lymphomas. Thus, TC-PTP may be a suitable molecular target for the treatment of B-cell lymphomas.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19755676      PMCID: PMC2788975          DOI: 10.1182/blood-2008-12-196709

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  31 in total

Review 1.  The myc oncogene: its role in transformation and differentiation.

Authors:  M D Cole
Journal:  Annu Rev Genet       Date:  1986       Impact factor: 16.830

2.  Epidermal growth factor receptor and the adaptor protein p52Shc are specific substrates of T-cell protein tyrosine phosphatase.

Authors:  T Tiganis; A M Bennett; K S Ravichandran; N K Tonks
Journal:  Mol Cell Biol       Date:  1998-03       Impact factor: 4.272

3.  Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas.

Authors:  L Pasqualucci; P Neumeister; T Goossens; G Nanjangud; R S Chaganti; R Küppers; R Dalla-Favera
Journal:  Nature       Date:  2001-07-19       Impact factor: 49.962

4.  Nuclear localization and cell cycle regulation of a murine protein tyrosine phosphatase.

Authors:  U Tillmann; J Wagner; D Boerboom; H Westphal; M L Tremblay
Journal:  Mol Cell Biol       Date:  1994-05       Impact factor: 4.272

5.  Murine embryonic fibroblasts lacking TC-PTP display delayed G1 phase through defective NF-kappaB activation.

Authors:  M J Ibarra-Sánchez; J Wagner; M T Ong; C Lampron; M L Tremblay
Journal:  Oncogene       Date:  2001-08-02       Impact factor: 9.867

6.  The protein tyrosine phosphatase TCPTP suppresses the tumorigenicity of glioblastoma cells expressing a mutant epidermal growth factor receptor.

Authors:  M Klingler-Hoffmann; M T Fodero-Tavoletti; K Mishima; Y Narita; W K Cavenee; F B Furnari; H J Huang; T Tiganis
Journal:  J Biol Chem       Date:  2001-12-07       Impact factor: 5.157

Review 7.  Oncogenic transcription factors in the human acute leukemias.

Authors:  A T Look
Journal:  Science       Date:  1997-11-07       Impact factor: 47.728

Review 8.  T-cell protein tyrosine phosphatase is a key regulator in immune cell signaling: lessons from the knockout mouse model and implications in human disease.

Authors:  Karen M Doody; Annie Bourdeau; Michel L Tremblay
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

9.  Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target.

Authors:  Ryan M Young; Ian R Hardy; Raedun L Clarke; Nicolai Lundy; Polly Pine; Brian C Turner; Terry A Potter; Yosef Refaeli
Journal:  Blood       Date:  2008-11-03       Impact factor: 22.113

10.  Impaired bone marrow microenvironment and immune function in T cell protein tyrosine phosphatase-deficient mice.

Authors:  K E You-Ten; E S Muise; A Itié; E Michaliszyn; J Wagner; S Jothy; W S Lapp; M L Tremblay
Journal:  J Exp Med       Date:  1997-08-29       Impact factor: 14.307

View more
  6 in total

Review 1.  The impact of phosphatases on proliferative and survival signaling in cancer.

Authors:  Goutham Narla; Jaya Sangodkar; Christopher B Ryder
Journal:  Cell Mol Life Sci       Date:  2018-05-03       Impact factor: 9.261

2.  IRF4 is a suppressor of c-Myc induced B cell leukemia.

Authors:  Simanta Pathak; Shibin Ma; Long Trinh; James Eudy; Kay-Uwe Wagner; Shantaram S Joshi; Runqing Lu
Journal:  PLoS One       Date:  2011-07-27       Impact factor: 3.240

Review 3.  Protein tyrosine phosphatases: promising targets in pancreatic ductal adenocarcinoma.

Authors:  Mariana Tannús Ruckert; Pamela Viani de Andrade; Verena Silva Santos; Vanessa Silva Silveira
Journal:  Cell Mol Life Sci       Date:  2019-04-13       Impact factor: 9.207

4.  Dynamic recruitment of protein tyrosine phosphatase PTPD1 to EGF stimulation sites potentiates EGFR activation.

Authors:  Pedro Roda-Navarro; Philippe I Bastiaens
Journal:  PLoS One       Date:  2014-07-25       Impact factor: 3.240

Review 5.  PTPN2 in the Immunity and Tumor Immunotherapy: A Concise Review.

Authors:  Jiachun Song; Jinxin Lan; Jiaping Tang; Na Luo
Journal:  Int J Mol Sci       Date:  2022-09-02       Impact factor: 6.208

6.  PTPN2 regulates the activation of KRAS and plays a critical role in proliferation and survival of KRAS-driven cancer cells.

Authors:  Zhangsen Huang; Mingzhu Liu; Donghe Li; Yun Tan; Ruihong Zhang; Zhizhou Xia; Peihong Wang; Bo Jiao; Ping Liu; Ruibao Ren
Journal:  J Biol Chem       Date:  2020-10-29       Impact factor: 5.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.